Design and synthesis of C-ring lactone- and lactam-based podophyllotoxin analogues as anticancer agents

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 2, 2010, Pages 242-246

  Singh, Pragya ^a   Faridi, Uzma ^a   Srivastava, Suchita ^a   Kumar, Jonnala Kotesh ^a   Darokar, Mahender Pandurang ^a   Luqman, Suaib ^a   Shanker, Karuna ^a   Chanotiya, Chandan Singh ^a   Gupta, Atul ^a   Gupta, Madan Mohan ^a   Negi, Arvind Singh ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

Anticancer; MTT assay; Osmotic fragility; Podophyllotoxin

Indexed keywords

3',4' DIHYDRO 4' (3,4,5 TRIMETHOXYPHENYL)ESTRA 1(10),2,4 TRIENO[3,2 B]PYRAN 2',17 DIONE; 3,4 DIHYDRO 5,6,7 TRIMETHOXY 4 (4 HYDROXY 3,5 DIMETHOXYPHENYL)QUINOLIN 2(1H) ONE; 3,4 DIHYDRO 5,7 DIMETHOXY 4 (3,4,5 TRIMETHOXYPHENYL)COUMARIN; 3,4 DIHYDRO 6,7 DIMETHOXY 4 (3,4,5 TRIMETHOXYPHENYL)COUMARIN; 3,4 DIHYDRO 6,7 METHYLENEDIOXY 4 (2 ACETYLOXY 3,5 DIMETHOXYPHENYL)COUMARIN; 3,4 DIHYDRO 6,7 METHYLENEDIOXY 4 (3,4,5 TRIMETHOXYPHENYL)COUMARIN; 3,4 DIHYDRO 6,7 METHYLENEDIOXY 4 (3,4,5 TRIMETHOXYPHENYL)QUINOLIN 2(1H) ONE; 3,4 DIHYDRO 6,7 METHYLENEDIOXY 4 (4 HYDROXY 3,5 DIMETHOXYPHENYL)QUINOLIN 2(1H) ONE; 3,4 DIHYDRO 7 METHOXY 4 (3,4,5 TRIMETHOXYPHENYL)COUMARIN; ANTINEOPLASTIC AGENT; CURCUMIN; ETOPOSIDE; LACTAM DERIVATIVE; LACTONE DERIVATIVE; PACLITAXEL; PODOPHYLLOTOXIN; PODOPHYLLOTOXIN DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DEMETHYLATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; ERYTHROCYTES; HEMOLYSIS; HUMANS; LACTAMS; LACTONES; MOLECULAR STRUCTURE; NEOPLASMS; PODOPHYLLOTOXIN;

EID: 76149120438     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.242     Document Type: Article

References (15)

1. Schrecker A. W., Hartwell J. L., J. Org. Chem., 21, 381- (1956).
2. Osheroff N., Zechiedrich E. L., Gale K. C., BioEssays, 13, 269-275 (1991).
3. Issell B. F., Cancer Chemother. Pharmacol., 7, 73-80 (1982).
4. Damayanthi Y., Lown J. W., Curr. Med. Chem., 5, 205-252 (1998).
5. Chang J. Y., Han F. S., Liu S. Y., Wang Z. Q., Lee K. H., Cheng Y. C., Cancer Res., 51, 1755-1759 (1991).
6. Cho S. J., Tropsha A., Suffness M., Cheng Y. C., Lee K. H., J. Med. Chem., 39, 1383-1395 (1996).
7. Lee K. H., Beers S. A., Mori M., Wang Z. Q., Kuo Y. H., Li L., Liu S. Y., Cheng J. Y., Chan F. S., Cheng Y. C., J. Med. Chem., 33, 1364-1368 (1990).
8. Zhou X. M., Wang Z. Q., Chang J. Y., Chen H. X., Cheng Y. C., Lee K. H., J. Med. Chem., 34, 3346-3350 (1991).
9. Xiao Z., Xiao Y.-D., Golbraikh A., Tropsha A., Lee K. H., J. Med. Chem., 45, 2294-2309 (2002).
10. Kamal A., Kumar A., Arifuddin M., Dastidar S. G., Bioorg. Med. Chem., 11, 5135-5142 (2003).
11. Huang T. S., Shu C. H., Shih Y. L., Huang H. C., Su Y. C., Chao Y., Yang W. K., Peng J. W., Cancer Lett., 110, 77-85 (1996).
12. Krow G. R., Org. React., 43, 251 (1993).
13. Li K., Foresee L. N., Tunge J. A., J. Org. Chem., 70, 2881-2883 (2005).
14. Woerdenbag H. J., Moskal T. A., Pras N., Malingré T. M., Farouk S., El-Feraly H., Kampinga H., Konings A. W. T., J. Nat. Prod., 56, 849-856 (1993).
15. Luqman S., Rizvi S. I., Asia Pac. J. Pharmacol., 16, 53-55 (2004).